Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized ...
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up ...
Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV ...
Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third ...
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...
The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?
Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it ...
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners ...
The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results